Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07047963
Starting soon Observational

Neuropsychological Evaluation in Intellectual Disability (ENDI)

NCT07047963 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-07-01
Last updated
2025-07-02

Condition(s) studied

Down Syndrome (Trisomy 21)NeuropsychologyCognitive AgingAlzheimer DiseaseAlzheimer Disease, Early Onset

Investigational drug(s) / intervention(s)

ENDI (Neuropsychological Evaluation in Intellectual Disability)

ENDI (Neuropsychological Evaluation in Intellectual Disability): This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.

Study summary

The goal of this observational study is to evaluate the acceptability ofpatients with trisomy 21 (T21) to perform the full battery of ENDI neurospychological tests and each of the subsets.

In this study, three types of population will be recruted : normotypic volunteers, patients with Intellectual Disability and patients T21carriers.

This study is separated into 2 phases :

* A the preliminary phase : this phase will be used to evaluate subtest design, ergonomics and understanding of instructions, and to identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company. In this phase, normotypical volunteers and patients with intellectual disabilities will be recruted to perform ENDI test battery.
* A main phase : this phase will enable to answer to the main objective. in this phase, patients with Trisomy 21 aged between 25 and 65 will be recruted to perform ENDI test battery.

Eligibility

Sex
ALL
Min age
25 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: Preliminary phase: 1. The inclusion criteria for the group of people with intellectual disabilities are as follows: * Participant who has received full information on the organization of the research and has not objected to his or her participation and to the use of his or her data. * Legal guardian of the participant, if applicable, who has received full information on the organization of the research and has not objected to participation and use of his/her data. * Age at inclusion: ≥ 25 and ≤ 65 years * Notion of intellectual disability in medical records * Access to the oral language of the participant with an intellectual disability: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills. * Enrolled in or benefiting from a social security scheme. 2. The inclusion criteria for the normotypic group are as follows: * Participant having received full information on the organization of the research and not having objected to his or her participation and to the use of his or her data. * Age at inclusion: ≥ 25 and ≤ 65 years * Affiliation with a social security scheme or beneficiary of such a scheme Main phase: Inclusion criteria are as follows: * Participant with T21 who has received full information on the organization of the research and has not objected to participation and use of his/her data * Legal guardian of the participant with T21, where applicable, who has received full information on the organization of the research and has not objected to his or her participation and the use of his or her data. * Person with trisomy 21 * Age at inclusion: ≥ 25 and ≤ 65 years * Access to the oral language of the participant with T21: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills. * Membership of a social security scheme or beneficiary of such a scheme Exclusion Criteria for both phases of the study are as follows: * Disabling motor and/or sensory impairments preventing completion of the tests * Insufficient command of the French language to complete the tests * Severe general medical condition or alcoholism (habitual consumption of 3 drinks/day or history of alcohol withdrawal) * History of stroke, severe head trauma, or cancer * Change in long-term medication within 8 weeks prior to evaluation * Refusal to participate by the subject and/or legal representative * Individuals referred to in Articles L.1121-5 to L.1121-7 of the French Public Health Code: * Pregnant women, women in labor, or breastfeeding mothers * Individuals deprived of liberty by judicial or administrative decision * Individuals undergoing psychiatric treatment under Article L.3213-1 of the French Public Health Code

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHRU de Nancy Vandœuvre-lès-Nancy Grand Est

More Central Hospital, Nancy, France trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07047963 on ClinicalTrials.gov ↗ ← All trials in France